期刊文献+

肾移植术后恶性肿瘤与HLA抗原频率的研究

A study on the relation between HLA antigen frequency and post-transplant malignant tumor
下载PDF
导出
摘要 目的探讨肾移植术后恶性肿瘤的发生与人类白细胞抗原(HLA)抗原频率的关系。方法对具有HLA分型的肾移植术后发生恶性肿瘤的107例患者进行HLA抗原频率分析。107例肾移植术后肿瘤患者分为4组,肾盂输尿管癌组,42例;膀胱肿瘤组,19例;其他泌尿系肿瘤组,14例;其他非泌尿系肿瘤组,32例。肾移植术后未发生恶性肿瘤的肾移植患者作为正常对照组,共计1 131例。结果在107例肾移植术后发生恶性肿瘤患者中,泌尿系统肿瘤75例,占肾移植术后发生恶性肿瘤患者的70.09%(75/107)。肾盂输尿管恶性肿瘤组HLA-A30、其他泌尿恶性肿瘤组的HLA-A32抗原频率与肾移植术后未发生恶性肿瘤的肾移植患者比较,差异有统计学意义(P均<0.05)。其他泌尿系肿瘤组中HLA-B62与肾移植术后未发生恶性肿瘤的肾移植患者比较,差异有统计学意义(P<0.05)。在HLA-DR抗原频率中,未发现与HLA相关的HLA-DR抗原,HLA-DR1在膀胱癌和其他泌尿癌中均未出现,HLA-DR17、DR10在肾盂癌和其他泌尿系癌中均未出现。在HLA-DQ抗原频率中,膀胱癌组HLA-DQ9的抗原频率与未发生恶性肿瘤的肾移植患者比较,差异有统计学意义(P<0.05)。结论某些HLA抗原与肾移植术后患者发生恶性肿瘤具有一定的关联。 Objective To study the relation between HLA antigen frequency and post-transplant malignant tumor. Methods HLA antigen frequency was analyzed in 107 post-transplant malignant tumor patients who had HLA typing tested. 107 patients were classified into four groups: the first group was composed of 42 patients with renal pelvic and ureteral carcinoma; the second group consisted of 19 of bladder tumor patients; the third group was composed of 14 pa-tients with other urinary tumorss; the last group were patients with other tumors. 1 131 post-transplant patients with-out malignant tumor were used as the control group. Transplant surgical operations were done during Jan, 1998 to Dec, 2004. Results In the 105 post-transplant malignant tumor patients, 73 (70.09%(75/107)) tumors were located in the urinary tract. In the renal pelvic and ureteral carcinoma group and other urinary tumor group, the relation between HLA-30 and HLA-32 frequency and post-transplant non-tumor patients was statistically significant (P&lt;0.05和P&lt;0.05). In pa-tients with other urinary tumors, the relation between HLA-B62 frequency and post-transplant non-tumor patients was sta-tistically significant (P&lt; 0.05). No HLA-DR antigen was detected, however, both DR1 and DR17 antigen were not de-tected in bladder cancer and other urinary cancers. DR10 was not detected in patients with pelvis cancer and other urinary cancer. In the bladder tumor group, the relation between HLA-DQ9 antigen frequency and post-transplant non-tumor pa-tients was statistically significant (P &lt; 0.05). Conclusion This study suggests that some HLA antigen is related to post-transplant malignant tumor.
出处 《北京医学》 CAS 2014年第10期854-857,共4页 Beijing Medical Journal
关键词 肾移植 人类白细胞抗原 恶性肿瘤 Renal transplant Human Leukocyte Antigen(HLA) Malignant tumor
  • 相关文献

参考文献6

二级参考文献39

  • 1瞿立辉,李群,陈江华,吴建永,王逸民,张建国,王苏娅,黄洪锋,何强.肾移植患者并发恶性肿瘤临床分析[J].中华泌尿外科杂志,2004,25(7):445-447. 被引量:21
  • 2彭明强,杨志豪,方自林.国内公开报道的肾移植后并发恶性肿瘤病例的总结分析[J].中华器官移植杂志,2005,26(5):269-271. 被引量:84
  • 3Diller R, Gruber A, Wohers H, et al. Therapy and prognosis of tumor of the genitourinary tract after kidney transplantation. Transplant Proc, 2005, 37: 2089-2092. 被引量:1
  • 4Yildirim Y, Ozyilkan O, Emiroglu R, et al. Early diagnosis of cancer in renal transplant patients: a single center experience. Asian Pac J Cancer Prey, 2006, 7: 336-339. 被引量:1
  • 5Vegso G, Toth M, Hidvegl M, et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res, 2007, 13: 63-69. 被引量:1
  • 6Marcen R, Pascual J, Tato AM, et al. Influence of on the prevalence of cancer after kidney transplantation. Transplant Proc, 2003, 35: 1714-1716. 被引量:1
  • 7Haberal M, Moray G, Kai'akayali H, et al. Effect of immunosuppressive treatment protocol on malignancy development in renal transplant patients. Transplant Proc,2002,34:2133-2135. 被引量:1
  • 8Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation, 2005, 80: 749-755. 被引量:1
  • 9Penn I. Occunrrence of cancers in immunosuppressed organ transplant recipients. Clin Transplant, 1998, 12:147-158. 被引量:1
  • 10Penn I. Cancers after cyclosporine therapy. Transplant Proc,1998, 20:276. 被引量:1

共引文献92

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部